Search Results - "Loon, Judith Van"

Refine Results
  1. 1
  2. 2

    Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): disparities between younger and older patients by Driessen, Elisabeth J, Aarts, Mieke J, Bootsma, Gerbern P, Loon, Judith G van, Janssen-Heijnen, Maryska L

    Published in Lung cancer (Amsterdam, Netherlands) (01-06-2017)
    “…Highlights • More curative-intent treatment and improved relative survival for NSCLC-patients • These trends were less profound among older patients •…”
    Get full text
    Journal Article
  3. 3

    Patterns of treatment and survival among older patients with stage III non-small cell lung cancer by Driessen, Elisabeth J.M., Schulkes, Karlijn J.G., Dingemans, Anne-Marie C., van Loon, Judith G.M., Hamaker, Marije E., Aarts, Mieke J., Janssen-Heijnen, Maryska L.G.

    Published in Lung cancer (Amsterdam, Netherlands) (01-02-2018)
    “…•Chemoradiotherapy was applied to 1/2 patients aged 65–74 and 1/5 patients aged ≥75.•Overall survival was poorer for patients aged ≥75 years compared to ages…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Geriatric Assessment for Older Patients with Non-small Cell Lung Cancer: Daily Practice of Centers Participating in the NVALT25-ELDAPT Trial by Driessen, Elisabeth J. M., van Loon, Judith G. M., Maas, Huub A., Dingemans, Anne-Marie C., Janssen-Heijnen, Maryska L. G.

    Published in Lung (01-08-2018)
    “…Introduction Geriatric assessment (GA) for older patients with lung cancer could provide insight into vulnerability, cognitive impairment, and risk of…”
    Get full text
    Journal Article
  7. 7

    Study Protocol of the NVALT25-ELDAPT Trial: Selecting the Optimal Treatment for Older Patients With Stage III Non–small-cell Lung Cancer by Driessen, Elisabeth J.M., Janssen-Heijnen, Maryska L.G., Maas, Huub A., Dingemans, Anne-Marie C., van Loon, Judith G.M.

    Published in Clinical lung cancer (01-11-2018)
    “…Patients aged 75 years or older with stage III non–small-cell lung cancer (NSCLC) are underrepresented in clinical trials, leading to a lack of evidence for…”
    Get full text
    Journal Article
  8. 8

    The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation by Witlox, Willem J A, Ramaekers, Bram L T, Zindler, Jaap D, Eekers, Daniëlle B P, van Loon, Judith G M, Hendriks, Lizza E L, Dingemans, Anne-Marie C, De Ruysscher, Dirk K M

    Published in Frontiers in oncology (26-07-2018)
    “…Non-small cell lung cancer (NSCLC) patients frequently develop brain metastases (BM), even though the initial imaging with brain CT or MRI was negative. Stage…”
    Get full text
    Journal Article
  9. 9

    Clinical evaluation of synthetic computed tomography methods in adaptive proton therapy of lung cancer patients by Taasti, Vicki Trier, Hattu, Djoya, Peeters, Stephanie, van der Salm, Anke, van Loon, Judith, de Ruysscher, Dirk, Nilsson, Rasmus, Andersson, Sebastian, Engwall, Erik, Unipan, Mirko, Canters, Richard

    Published in Physics and imaging in radiation oncology (01-07-2023)
    “…•Use of synthetic CTs for adaptive proton therapy of lung cancer patients.•42 patients included, both with and without anatomical changes.•Evaluation of…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project by Defourny, Noemie, Perrier, Lionel, Borras, Josep-Maria, Coffey, Mary, Corral, Julietta, Hoozée, Sophie, Loon, Judith van, Grau, Cai, Lievens, Yolande

    Published in Radiotherapy and oncology (01-09-2019)
    “…Highlights•ESTRO-HERO tool, applied to Europalia, generates economic evidence for radiotherapy. •Detailed cost estimates capture RT treatments diversity,…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? by van Loon, Judith, Dr, Grutters, Janneke, PhD, Macbeth, Fergus, FRCR

    Published in The lancet oncology (01-04-2012)
    “…Summary Technical innovations in radiation oncology—eg, intensity-modulated radiotherapy, stereotactic radiotherapy, and particle therapy—can be developed…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective? by Vanneste, Ben G.L, Pijls-Johannesma, Madelon, Van De Voorde, Lien, van Lin, Emile N, van de Beek, Kees, van Loon, Judith, Ramaekers, Bram L, Lambin, Philippe

    Published in Radiotherapy and oncology (01-02-2015)
    “…Abstract Background and purpose To compare the cost-effectiveness of treating prostate cancer patients with intensity-modulated radiation therapy and a spacer…”
    Get full text
    Journal Article
  18. 18

    Prediction models for treatment-induced cardiac toxicity in patients with non-small-cell lung cancer: A systematic review and meta-analysis by Tohidinezhad, Fariba, Pennetta, Francesca, van Loon, Judith, Dekker, Andre, de Ruysscher, Dirk, Traverso, Alberto

    “…•The cardiac event rate in the included studies ranged between 3.9% and 49.6%•Cardiac history was the most predictive factor for events after…”
    Get full text
    Journal Article
  19. 19
  20. 20